Company Profile

Industry Sector: Pharmaceuticals

Company Overview: DEKK-TEC was formed in 1983, and has utilized government and private funding to effectively develop new therapies and clinical development candidates for the treatment of cancer, pre-cancerous lesions, and women’s health issues. We have previously partnered two of our pipeline products to Biotech/Pharmaceutical companies who have successfully driven these compounds into Phase II clinical development.

Our present objective is to continue to create and develop clinical stage investment/partnership opportunities based on our current novel cancer therapeutic agent DM-CHOC-PEN.

Target Market(s): -Oncology (CNS & metastatic tumors, solid tumors)

Key Value Drivers

Technology:
DM-CHOC-PEN – novel anti-cancer agent able to cross the blood brain barrier

Competitive Advantage: DM-CHOC-PEN is our proprietary investigational alkylating cancer agent with the specific advantage of being able to cross the blood brain barrier. Current brain cancer drugs do not cross the blood brain barrier so must be given intra-cranially where they cause significant toxicity and have shown only modest efficacy. DM-CHOC-PEN, which can be given intravenously because it crosses the blood brain barrier, has shown superior efficacy to available therapies in pre-clinical studies, as well as a favorable safety, toxicity and PK/PD profiles. As such, DM-CHOC-PEN represents a significant new cancer therapy opportunity to address a large unmet medical need.

Plan & Strategy: -Initiate a Phase I/II with IV DM-CHOC-PEN in patients with brain metastases refractory to the current standard of care.

Management

Leadership:
- Lee Roy Morgan, MD, PhD - CEO
  Organic chemist, pharmacologist, & medical oncologist
- Andrew Rodgers, PhD - Director of Research & Regulatory Affairs
  Analytical chemist, FDA regulatory affairs
- Lisa Stokes-Hasten, BSRN – Clinical Research
  Certified oncology nurse
- Leo Mensink, MBA - Director of European Affairs
  EU financial specialist

Scientific Advisory Board:
- Lesley A. Meng, MD
  Phase I Director, Arizona Cancer Institute, Scottsdale, AZ

Product Pipeline

<table>
<thead>
<tr>
<th>Compound</th>
<th>IND</th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>NDA</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HPV Related Cancers</td>
</tr>
<tr>
<td>IPM (ZIO-201)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sarcoma/Others</td>
</tr>
<tr>
<td>Progesterone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Premenstrual Syndrome</td>
</tr>
<tr>
<td>DM-CHOC-PEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CNS Cancers/others</td>
</tr>
<tr>
<td>Camptothecins</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cancer</td>
</tr>
<tr>
<td>HOO-IFOS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cancer</td>
</tr>
<tr>
<td>Pyrroles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cancer</td>
</tr>
</tbody>
</table>